Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCAT2 | O15382 | 6/20 | 0.33 |
| ▸ | BCAT1 | P54687 | 2/20 | 0.33 |
| ▸ | MAT2A | P31153 | 1/20 | 0.30 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22101439 | 0.83 | — | — | |
| SCHEMBL22101865 | 0.82 | KCNQ3 (0.31) | — | |
| SCHEMBL22101360 | 0.82 | MAPT (0.35) | MAT2ACXCR2 | |
| SCHEMBL22101361 | 0.80 | KDM4E (0.34) | MAT2ACXCR2 | |
| SCHEMBL22101413 | 0.76 | MAPKAPK2 (0.37) | — | |
| SCHEMBL22393704 | 0.75 | MAPT (0.36) | MAT2ACXCR2 | |
| SCHEMBL22101400 | 0.73 | CXCR2 (0.38) | BCAT2BCAT1MAT2ACXCR2 | |
| SCHEMBL22101725 | 0.73 | GRIN1 (0.40) | MAT2ACXCR2 | |
| SCHEMBL22393919 | 0.72 | KDM5B (0.36) | BCAT2MAT2ACXCR2 | |
| SCHEMBL22101411 | 0.72 | KDM5B (0.36) | BCAT2MAT2ACXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230035184-A1 | DIARYLTHIOHYDANTOIN COMPOUND AS ANDROGEN RECEPTOR ANTAGONIST | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-02-02 | — | — | US | disclosed |
| US-11332465-B2 | Diarylthiohydantoin compound as androgen receptor antagonist | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-05-17 | — | — | US | disclosed |
| US-20220009925-A1 | CRYSTAL OF DIARYLTHIOHYDANTOIN COMPOUND | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-01-13 | — | — | US | disclosed |
| US-20200277290-A1 | DIARYLTHIOHYDANTOIN COMPOUND AS ANDROGEN RECEPTOR ANTAGONIST | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-09-03 | — | — | US | disclosed |
| EP-3666772-A1 | DIARYLTHIOHYDANTOIN COMPOUND AS ANDROGEN RECEPTOR ANTAGONIST | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2020-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230035184-A1 | DIARYLTHIOHYDANTOIN COMPOUND AS ANDROGEN RECEPTOR ANTAGONIST | AR, NR5A1, LHCGR | BCAT2 758/4885BCAT1 838/4885MAT2A 1257/4885 |
| US-20200277290-A1 | DIARYLTHIOHYDANTOIN COMPOUND AS ANDROGEN RECEPTOR ANTAGONIST | AR, NR5A1, LHCGR | BCAT2 758/4885BCAT1 838/4885MAT2A 1257/4885 |
| US-11332465-B2 | Diarylthiohydantoin compound as androgen receptor antagonist | AR, NR5A1, LHCGR | BCAT2 758/4885BCAT1 838/4885MAT2A 1257/4885 |
| US-20220009925-A1 | CRYSTAL OF DIARYLTHIOHYDANTOIN COMPOUND | SHBG, NR5A1, CYP21A2 | BCAT2 436/4885BCAT1 718/4885MAT2A 920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.